NASDAQ · TDAC
Translational Development Acquisition Corp.
$10.85$0.00 (0.0%)
Translational Development Acquisition Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.91% below the high.
Loading market information…
NYSE · XXI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Twenty One Capital Inc’s quoted price sits in the lower half of its reported 52-week range, 70.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Twenty One Capital Inc’s next earnings report is currently expected on Nov 5, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Twenty One Capital Inc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Twenty One Capital, Inc. is focused on Bitcoin-related business. It offers shareholders a differentiated opportunity to gain exposure to Bitcoin through the equity markets. The company was founded on March 7, 2025 and is headquartered in Austin, TX.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.85$0.00 (0.0%)
Translational Development Acquisition Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.91% below the high.
$10.52-$0.01 (-0.09%)
Sizzle Acquisition Corp. II’s quoted price sits in the upper half of its reported 52-week range, 0.19% below the high.
$10.80+$0.01 (+0.05%)
Cantor Equity Partners I, Inc. Class A Ordinary Shares’s quoted price sits in the upper half of its reported 52-week range, 1.55% below the high.
$10.64+$0.03 (+0.27%)
Gesher Acquisition Corp. II’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$10.85-$0.01 (-0.09%)
Newbury Street II Acquisition Corp’s quoted price sits in the lower half of its reported 52-week range, 10.63% below the high.
$7.73-$0.69 (-8.19%)
Melar Acquisition Corp. I’s quoted price sits in the lower half of its reported 52-week range, 53.15% below the high.
$10.33+$0.01 (+0.1%)
HCM III Acquisition Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.89+$0.01 (+1.63%)
GCL Global Holdings Ltd Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 80.29% below the high.
